
Opinion|Videos|September 6, 2024
Future Directions for Type 2 Inflammation Management
Author(s)Reynold A. Panettieri Jr, MD
Reynold A. Panettieri Jr., MD, examines the application of biologic therapies in the treatment of respiratory conditions.
Advertisement
Episodes in this series

- Biologics are currently available for asthma management and being studied in COPD patients. Where do you envision the potential place of biologic therapies in the treatment algorithm for patients with type 2 inflammation-driven COPD?
- How does the route of administration impact the treatment selection?
- What emerging therapies for type 2 inflammation related to respiratory diseases are you most excited about? What are clinical trial data showing in terms of exacerbation and hospitalization rates, patient quality of life, and general disease management?
Advertisement
Related to this article

Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.

Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.

Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.

Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.

The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
Advertisement
Advertisement
Trending on AJMC
1
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
2
Study Finds Possible Deep Endometriosis in 7% of Postmenopausal Women
3
AHIP's Jeanette Thornton on Prior Authorization Reform, Midterms
4
Early-Onset Cancers Often Found Late as Screening Gaps Persist
5



